An in silico designed Fusion Inhibitor consisting of five cancer filtered conserved pharmacophoric chemical fragments with Greatly Promising Pharmaco-Mimic Properties to a Rationally Engineered Wilms' Tumor Peptide as a future computer generated hyper-molecule for the potential treatment of the acute myeloid leukemia.

Wilms’ Tumour 1 (WT1) is a zinc finger transcription factor that is overexpressed in acute myeloid leukaemia (AML). Its restricted expression in normal tissues makes it a promising target for novel immunotherapies aiming to accentuate the cytotoxic T lymphocyte (CTL) response against AML. It has been previously reported a phase I/II clinical trial of subcutaneous peptide vaccination with two separate HLA-A2-binding peptide epitopes derived from WT1, together with a pan-DR binding peptide epitope (PADRE), in Montanide adjuvant. Here, in Biogenea we have for the first time discovered an in silico designed Fusion Inhibitor consisting of five conserved cancer-related pharmacophores with Greatly Promising PharmacoMimic Properties to a Rationally Engineered Anti-Wilms'Tiumor Peptide.